National Lung Cancer Audit Annual Report 2018

This report represents the culmination of nearly two years of patient care and follow up, data collection, data analysis and interpretation. Its purpose is to understand the current quality of care and outcomes for patients with lung cancer, to celebrate good practice and to highlight variability, to ensure that all patients have access to the best care.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news

Related Links:

Conclusions: While case reports cannot be considered as proof of efficacy, these cases added to others of patients treated with the same method would suggest that this is a viable option for those patients whose disease cannot be treated successfully with other modalities. PMID: 31202206 [PubMed - in process]
Source: Alternative Therapies in Health and Medicine - Category: Complementary Medicine Authors: Tags: Altern Ther Health Med Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Contributors : Yan Zhang ; Yongyue Wei ; Jingjing Ben ; Chen QiSeries Type : Expression profiling by arrayOrganism : Mus musculusMetastasis is the key determinant of poor prognosis for advanced-stage NSCLC patients. Although an important contributor to metastasis is cross-talk between tumor-associated macrophages (TAMs) and tumor cells, its regulation is not fully understood. Expressed primarily in macrophages, scavenger receptor A1 (SR-A1) has been associated with lung tumorigenesis. Here, the mechanistic basis for the involvement of SR-A1 in lung cancer prognosis was investigated using population genetics, transcriptomic...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
Publication date: Available online 14 June 2019Source: Personalized Medicine UniverseAuthor(s): Ayaka Nakamura, Minako Abe, Yasuha Ono, Yukie Saeki, Fumika Kono, Hazuki Sakuma, Ayumi Morokuma, Yoshimori Ishihara, Hiroyuki AbeAbstractThe global incidence and mortality rates of colorectal cancer is rising, and has surpassed lung cancer as the highest incidence of all types of cancers in Japan [1]. Standard treatments include surgery and chemotherapy, however immunotherapy using Dendritic Cell (DC) vaccines is also recognized as an effective treatment for many cancers including colorectal cancer. DCs are the most potent antig...
Source: Personalized Medicine Universe - Category: Drugs & Pharmacology Source Type: research
ConclusionThis new method can enable repeatable nationwide measurement of cancer diagnostic timeliness in England and identifies actionable variation to inform early diagnosis interventions and target future research.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
AbstractPurposeBased on an exceptionally durable response to pemetrexed observed in some patients with metastatic NSCLC, the predictive value of pemetrexed sensitivity to outcomes of subsequent systemic treatment was investigated.MethodsWe retrospectively reviewed the patients with metastatic non-squamous NSCLC treated with pemetrexed monotherapy as their first- or second-line chemotherapy between November 2006 and February 2015. Good (top 5% longest) and poor responders (bottom 12% shortest) were defined according to the duration of pemetrexed maintenance. The first and second post-pemetrexed (PP) systemic treatments were...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
In this study, we found that TLR1/TLR2 expression predicted favorable prognosis of lung cancer patients. In the related mice tumor model, TLR1/TLR2 activation by synthetic bacterial lipoprotein (BLP), a TLR1/2 agonist, greatly inhibited tumor growth and selectively decreased monocytic MDSCs (M-MDSCs). Furthermore, BLP treatment redirected M-MDSC differentiation towards M1 macrophage through JNK pathway, and thus blocked the suppressive activity of M-MDSCs in a TLR2-dependent manner. Therefore, our data demonstrated that TLR2 could be a promising biomarker and a potential immunotherapeutic target for lung cancer.
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
This study demonstrates that NSCLC cells resistant to gefitinib (GR cells) displayed a significantly higher microsomal prostaglandin E synthase-1 (mPGES-1) expression and activity than parental cells. Overexpression of mPGES-1/prostaglandin E-2 (PGE-2) signaling in GR cells was associated with acquisition of mesenchymal and stem-like cell properties, nuclear EGFR translocation and tolerance to cisplatin. mPGES-1 inhibition reduced mesenchymal and stem-like properties, and nuclear EGFR translocation in GR cells. Consistently, inhibition of mPGES-1 activity enhanced sensitivity to cisplatin and responsiveness to gefitinib in...
Source: Prostaglandins and Other Lipid Mediators - Category: Lipidology Source Type: research
This study aimed to clarify whether CT-histogram analysis of tumors can be used to classify patients with clinical stage 0-IA non-small cell lung cancer (c0-IA NSCLC) according to pathological lymph node (pN) status.MethodsPredictive factors associated with pN metastasis (pNM) were identified from the derivation dataset including 629 patients with c0-IA NSCLC who underwent complete resection with lymph node dissection (surgeries between 2008 and 2013). The validation dataset including 238 patients (surgeries between 2014 and 2015) were subsequently re-evaluated. Clinico-surgical factors, including CT-histogram parameters o...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
A Prediction Rule for Overall Survival in Non-Small-Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm. Dis Markers. 2019;2019:8435893 Authors: Zhu WY, Fang KX, He JY, Cui R, Zhang YK, Le HB Abstract We sought to develop and validate a clinical nomogram model for predicting overall survival (OS) in non-small-cell lung cancer (NSCLC) patients with resected tumors that were 30 mm or smaller, using clinical data and molecular marker findings. We retrospectively analyzed 786 NSCLC patients with a pathological tumor size less than 30 mm who underwent surgery betwee...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
More News: Cancer | Cancer & Oncology | Health | Lung Cancer